Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 2125-2134

  Widemann, Brigitte C ^a   Balis, Frank M ^a   Murphy, Robert F ^a   Sorensen, J Mel ^a   Montello, Michael J ^a   O'Brien, Michelle ^a   Adamson, Peter C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYMETHOTREXATE; CARBOXYPEPTIDASE G2; CREATININE; DRUG METABOLITE; FOLINIC ACID; METHOTREXATE; PENTETATE TECHNETIUM TC 99M; THYMIDINE; ANTIDOTE; ANTINEOPLASTIC ANTIMETABOLITE; CARBOXYPEPTIDASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; ERYTHEMA; FEMALE; FLUSHING; GLOMERULUS FILTRATION RATE; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RASH; SKIN TINGLING; SOMNOLENCE; STOMACH CANCER; TREMOR; VERTIGO; ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; KIDNEY; KIDNEY DISEASE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PRESCHOOL CHILD; SARCOMA;

ADOLESCENT; ADULT; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; CARBOXYPEPTIDASES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; KIDNEY; KIDNEY DISEASES; LEUCOVORIN; LEUKEMIA, LYMPHOCYTIC, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; METHOTREXATE; MIDDLE AGED; SARCOMA; THYMIDINE;

EID: 0030611877     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.2125     Document Type: Article

References (39)

1. Frei E, Blum RH, Pitman SW, et al: High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med 68:370-376, 1980
2. Jolivet J, Cowan KH, Curt GA, et al: The pharmacology and clinical use of methotrexate. N Engl J Med 309:1094-1104, 1983
3. Masson E, Relling MV, Synold TW, et al: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J Clin Invest 97:73-80, 1996
4. Chan H, Evans WE, Pratt CB: Recovery from toxicity associated with high-dose methotrexate: Prognostic factors. Cancer Treat Rep 61:797-804, 1977
5. Von Hoff DD, Penta JS, Helman LJ, et al: Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep 61:745-748, 1977
6. Allegra CJ: Antifolates, in Chabner BA, Collins JM (eds): Cancer Chemotherapy. Philadelphia, PA, Lippincott, 1990, pp 110-153
7. Jürgens H, Beron G, Winkler K: Toxicity associated with combination chemotherapy for osteosarcoma: A report of the cooperative osteosarcoma study (COSS 80). J Cancer Res Clin Oncol 106:14-18, 1983 (suppl)
8. Abelson HT, Fosburg MT, Beardsley GP, et al: Methotrexateinduced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1:208-216, 1983
9. Condit PT, Chanes RE, Joel W: Renal toxicity of methotrexate. Cancer 23:126-131, 1969
10. Jacobs SA, Stoller RG, Chabner BA, et al: 7-Hydroxymethotrexate as a urinary metabolite in human subjects and Rhesus monkeys receiving high dose methotrexate. J Clin Invest 57:534-538, 1976
11. Takami M, Kuniyoshi Y, Oomukai T, et al: Severe complications after high-dose methotrexate treatment. Acta Oncol 34:611-612, 1995
12. Kawabata K, Makino H, Nagake Y, et al: A case of methotrexate-induced acute renal failure successfully treated with plasma perfusion and sequential hemodialysis. Nephron 71:233-234, 1995
13. Lawrenz-Wolf B, Wolfrom C, Frickel C, et al: Schwere renale Methotrexat-Ausscheidungsstörung nach Hochdosis-Therapie. Klin Pädiatr 206:319-326, 1994
14. Pinedo HM, Zaharko DS, Bull JM, et al: The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res 36:4418-4424, 1976
15. Bleyer WA: The clinical pharmacology of methotrexate. Cancer 41:36-51, 1978
16. Howell SB, Herbst K, Boss GR, et al: Thymidine requirements for the rescue of patients treated with high-dose methotrexate. Cancer Res 40:1824-1829, 1980
17. Grem JL, King SA, Sorensen JM, et al: Clinical use of thymidine as a rescue agent from methotrexate toxicity. Invest New Drugs 9:281-290, 1991
18. Hande KR, Balow JE, Drake JC, et al: Methotrexate and hemodialysis. Ann Intern Med 87:495-496, 1977
19. Howell SB, Blair HE, Uren J, et al: Hemodialysis and enzymatic cleavage of methotrexate in man. Eur J Cancer 14:787-792, 1978
20. Gibson TP, Reich SD, Krumlovsky FA, et al: Hemoperfusion for methotrexate removal. Clin Pharmacol Ther 23:351-355, 1977
21. Molina R, Fabian C, Cowley B: Use of charcoal hemoperfusion with sequential hemodialysis to reduce serum methotrexate levels in a patient with acute renal insufficiency. Am J Med 82:350-352, 1987
22. Relling MV, Stapleton FB, Ochs J, et al: Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 62:884-888, 1988
23. Albrecht AM, Boldizsar E, Hutchison DJ: Carboxypeptidase displaying differential velocity in hydrolysis of methotrexate, 5-methyltetrahydrofolic acid, and leucovorin. J Bacteriol 134:506-513, 1978
24. 1. J Biol Chem 246:7207-7213, 1974
25. Chabner BA, Johns DG, Bertino JR: Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature 239:395-397, 1972
26. 1 - A selective approach to the therapy of central nervous system tumors, in Kisliuk RL, Brown GM (eds): Chemistry and Biology of Pteridines. New York, NY, Elsevier, 1979, pp 629-633
27. Abelson HT, Kufe DW, Skarin AT, et al: Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep 65:137-140, 1981 (suppl 1)
28. 2 in Rhesus monkeys. J Clin Oncol 10:1359-1364, 1992
29. 2 gene and its expression in Escherichia coli and Pseudomonas putida. J Bacteriol 156:1222-1227, 1983
30. 2 from Pseudomonas sp. strain RS-16. Eur J Biochem 148:447-453, 1985
31. 2 rescue after high-dose methotrexate. J Clin Oncol 14:2145-2149, 1996
32. 2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer 76:521-526, 1995
33. National Cancer Institute: Investigator's Handbook: Guidelines for Reporting Adverse Drug Reactions. Bethesda, MD, Cancer Therapy Evaluation Program, Division of Cancer Treatment, 1993
34. Brandsteterova E, Seresova O, Miertus S, et al: HPLC determination of methotrexate and its metabolite in serum. Neoplasma 37:395-403, 1990
35. Gibaldi M, Perrier D: Pharmacokinetics (ed 2). New York, NY, Dekker, 1982
36. Albertioni F, Rask C, Eksborg S, et al: Evaluation of clinical assays for measuring high-dose methotrexate in plasma. Clin Chem 42:39-44, 1996
37. 2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol 12:471-477, 1995
38. 10-methylpteroic acid after high-dose methotrexate. Clin Pharm Ther 26:63-72, 1979
39. Stark AN, Jackson G, Carey PJ, et al: Severe renal toxicity due to intermediate-dose methotrexate. Cancer Chemother Pharmacol 24:243-245, 1989